Lindevall Returns as CEO of Encorium
CEO musical chairs continues at Wayne, Pa.-based contract research organization (CRO) Encorium . The company has reappointed Dr. Kai Lindevall as CEO, replacing David Ginsberg who left the company last summer when Encorium sold its U.S. business to Pierrel Research USA and Ginsberg became CEO there. Ginsberg had replaced Lindevall as CEO in September 2008. Lindevall, who replaced Kenneth Borow, M.D., as CEO in February 2008, has served as executive chairman since Ginsberg became CEO. Board member Shahab Fatheazam will serve as Encorium’s new chairman.
Other personnel news from around the industry:
Bob Scott-Edwards, president of ICON Central Laboratories (part of ICON), has retired after almost 10 years with the company. He is succeeded by Tom O’Leary, formerly senior vice president and global head of data management for ICON Clinical Research. Under Scott-Edwards’ tenure, ICON created a network of central labs in New York, Dublin, Ireland, Singapore and India. O’Leary joined ICON in 2001 and became global head of data management in 2006. Before joining ICON, he held senior data management, project management and resource management positions at SmithKline, Beecham and GlaxoSmithKline.
Pennsylvania-based CRF Health named Andrew Babington to the position of vice president for EU business development. Babington has 15 years of experience in the pharmaceutical and research industries, working in strategic sales planning and business development for Kendle, Quintiles, Reliance Clinical Research Services, AB BIODISK and Sandoz, Novartis, among others. Most recently, Babington was vice president for global business development for Encorium Oy.
New Jersey- based pharmaceutical services company i3 announced the following personnel changes: Brian Kelly was appointed group president for i3 Innovus, i3 Drug Safety, and i3 Pharma Informatics business units; Tracy Ken Tsuetaki was named president of i3 Research; and Andrew Chong was appointed regional vice president for i3 in the Asia-Pacific region. Prior to joining i3, Kelly was global vice president and general manager in Covance’s Central Laboratory Services business. Tsuetaki also joined i3 from Covance, where he was chief marketing officer and a corporate vice president. Chong comes to i3 from Genentech, where he led the Asia-Pacific region in the Office of International Development.
Cambridge, MA- based Outcome Sciences appointed Leanne Larson as vice president, strategic development. Prior to joining Outcome, Larson served as vice president at Sg2 Healthcare Intelligence, where she led the Cancer Intelligence Program, providing clinical and operational guidance to hospital cancer programs. She previously worked at ICON Lifecycle Sciences Group, leading the Registry Consulting group.
Columbus, OH-based Prologue Research appointed Art Ziegler to the role of vice president of business development. Ziegler brings with him 25 years of clinical research and business development experience. Prior to joining Prologue, Ziegler held various positions at pharmaceutical, site management, and contract research organizations.